

EZZ

FY22 Results
Presentation

13 October 2022



analyst use only

DISCLAIMER

This document has been prepared by EZZ Life Science Holdings Limited ACN 608 363 604 (**Company**). By accepting a copy of this document you warrant and undertake to the Company that you agree to be bound by the terms and conditions set out below.

This document is not a prospectus, product disclosure statement or other offer document under Australian law or under any other law and has not been filed, registered or approved by regulatory authorities in any jurisdiction. This document does not constitute an offer, invitation, solicitation or recommendation to acquire any shares in the Company. The information contained in this document is not intended to be relied upon as advice or a recommendation to investors and does not take into account the investment objectives, financial situation, taxation situation or needs of any particular investor. An investor must not act on the basis of any matter contained in this document but must make its own assessment of the Company and conduct its own investigations and analysis. Investors should assess their own individual financial circumstances and consider talking to a financial adviser, professional adviser or consultant before making any investment decision. The information contained in this document is supplied in summary form and does not contain all information necessary to make an investment decision.

Neither the Company nor any of its directors, officers, employees, contractors, agents or advisers (**Limited Party**) makes any representations or warranties, express or implied, as to or takes responsibility for, the accuracy, reliability, completeness or fairness of the information, opinions, forecasts, reports, estimates and conclusions contained in this document. No Limited Party represents or warrants that this document is complete or that it contains all information about the Company that a prospective investor may require in evaluating a possible investment in the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability, including, without limitation, any liability arising out of fault, negligence or omission on the part of any person, for any loss or damage arising from the use of, or reliance on, information contained in this document or otherwise arising in connection with it.

Certain statements in this document constitute forward looking statements and comments about future events, including with respect to the financial condition, results of operations and business of the Company and certain plans and objectives of the management of the Company. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Forward looking statements are provided as a general guide only, and should not be relied on as an indication or guarantee of future performance. Given these uncertainties, you are cautioned to not place undue reliance on any forward looking statement. Past performance is not indicative of future performance and no guarantee of future returns is implied or given. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company. No Limited Party or any other person makes any representation as to the accuracy or likelihood of the fulfilment of any forward-looking statements, or gives any assurance or guarantee that the occurrence of the events expressed or implied in any forward looking statements in this document will occur.

AGENDA

Section	Topic	Presenter	Page
1	Executive summary	Mark Qin, Interim CEO, COO and co-founder	01 – 02
2	Company overview	Mark Qin, Interim CEO, COO and co-founder	03 – 07
3	Financial information	Anthony Guarna, CFO	08 – 12
4	Strategy and outlook	Anthony Guarna, CFO	13 – 14

1. EXECUTIVE SUMMARY

Mark Qin,
Interim CEO, COO and co-founder, EZZ Life Science Holdings Limited

Section	Topic	Page
1.1	Financial overview	01
1.2	Operational overview	02



anal use only
EZZ

1.1 FINANCIAL OVERVIEW

Revenue

\$15.0M

Down by 32.6% from FY21

EBITDA

\$1.8M

Down by 34.7% from FY21

NPAT

\$1.3M

Down by 35.4% from FY21

EPS

3.1c

Down by 48.3% from FY21

Gross Margin

50.0%

Down from 55.9% in FY21

Cash Conversion Ratio

1.4

Up from 0.1 in FY21

Debt to Equity Ratio

0.0%

Unchanged from FY21

Final dividend per share

0.45c

in October 2022

1.2 OPERATIONAL OVERVIEW

Research and Development

7 new products
under the EZZ brand

Channel Diversification

4 new channels
added to e-commerce strategies

Marketing ROI

81.1%
Up from 53.2% in FY21

Average Sites Traffic Growth

30.7%/month
from Oct 2021 to Sep 2022

Revenue from the Best-Selling Product

17.0%
up from 15% in FY21

Revenue from the Best Performing Channel

15.5%
down from 43.0% in FY21

Revenue from the Largest Customer

11.5%
up from 7.0% in FY21

Market development

5 new regions
entered for EZZ brand distribution

2. COMPANY OVERVIEW

Mark Qin,
Interim CEO, COO and co-founder, EZZ Life Science Holdings Limited

Section	Topic	Page
2.1	Who we are	03
2.2	What we do	04
2.3	Our history	05
2.4	Why we are different	06
2.5	Share information	07

EZZ



2.1 WHO WE ARE

Vision, Mission and Values



Vision

Improve quality of life and human health



Mission

Become one of the leading life science companies within Australia and New Zealand



Values

Accelerate innovation to market

Value Creating Strategies

- 1 Strengthen existing operations through performance excellence
- 2 Capture growth opportunities through entrepreneurial initiatives
- 3 Enable new verticals through value-accretive opportunities

Delivering Return to Shareholders



Employ strong management teams to drive long-term earnings growth, and deploy best practice principles in operational execution.



Continuously improve working capital efficiency.



Ensure a highly disciplined approach in capital expenditure, and invest only in opportunities with a return exceeding the cost of capital.

2.2 WHAT WE DO

EZZ

We formulate, produce and market health and wellbeing products under the brand of EZZ, with a focus on products with significant demand from the market by consumers.

Top 3 Products by Revenue in FY22



NMN 150,000 mcg



L-Lysine Growth Capsule



Daily Energy and Wellbeing

EAORON

We are an exclusive wholesale distributor of EAORON branded skin care products in Australia and New Zealand to pharmacies, supermarkets and specialist retailers.


Top 3 Products by Revenue in FY22



Hyaluronic Acid Collagen Hydrating Face Mask



Hyaluronic Acid Collagen Essence



Instant Brightening Face Mask

EZZ

2.3 OUR HISTORY

Started operations as a wholesale distributor of the EAORON branded skincare products

Commenced development, production and marketing of the EZZ branded health supplements

Became an exclusive distributor of the EAORON branded products in Australia and New Zealand

Listed on the Australian Securities Exchange (ASX) via an over-subscribed initial public offer by issuing 12 million fully paid ordinary shares at 50 cents raising \$6 million

Continue to execute Five-Year Strategic Plan and create sustainable growth

...

2018

2019

2020

2021

2022

2.4 WHY WE ARE DIFFERENT

Demand Driven Research and Development + Strong Marketing Capabilities

Chemists
600+


Specialist Retailers
130+

Grocery Retailers
200+

Supermarkets
7,500+

E-commerce
750+

#1 among the best selling nutrition and food products in the last 30 days on Douyin



#1 among The best selling children's calcium, iron and zinc products in the last 30 days on Tmall Global



#1 among the highest rated children's calcium, iron and zinc products the last in 180 days




#1 among the most re-ordered children's calcium, iron and zinc products in 365 days



2.5 SHARE INFORMATION

Share Price Movements



Share Information

ASX code:	EZZ
Close on 11 October 2022	\$0.305
Shares on Issue:	42.8M
Market cap 11 October 2022:	\$13M
52-week price range:	\$0.27-\$0.55

Top Five Shareholders

Macquarie Holdings Pty Ltd	39.8%
JNJ Mok Pty Ltd	26.5%
Yong Cao	4.1%
Haitao Zheng	1.1%
Jing Chen	1.1%

3. FINANCIAL OVERVIEW

Anthony Guarna,
CFO, EZZ Life Science Holdings Limited

Section	Topic	Page
3.1	Revenue	08
3.2	Margins	09
3.3	Financial position	10
3.4	Working capital	11
3.5	Cash flows	12





EZZ

3.1 REVENUE

Revenue Drivers

Revenue by Segment


Internal Use Only
 EZZ




EZZ

3.2 MARGINS


Gross Margin




EBITDA Margin



Net Margin




3.3 FINANCIAL POSITION




¹ Excluding lease liabilities

3.4 WORKING CAPITAL

Working Capital Movements



Cash Conversion Cycle




3.5 CASH FLOWS

Cash Flows Movements

Cash Flows from Operation: Up by 7.5x from FY21

Cash Flows from Investment

Cash Flows from Financing



4. STRATEGY AND OUTLOOK

Mark Qin,
Interim CEO, COO and co-founder, EZZ Life Science Holdings Limited


Section	Topic	Page
4.1	Strategic focus	13
4.2	Outlook	14

FOR A HEALTHIER LIFE



EZZ

4.1 STRATEGIC FOCUS



4.2 FY23 OUTLOOK

10+
New
products

Invest in research and development to accelerate innovation to the market with a focus on high margin and high demand products.


Domestic
markets

Complement the bricks and mortar distribution points in Australia and New Zealand with digital strategies through EZZ and EAORON branded eCommerce sites to drive organic growth.


Digital
strategy

Invest in digital oriented marketing activities for improved search engine optimisation results, increased traffic, better conversion rate, greater brand awareness.


Manufacturing
facility

Execute the plan to have an in-house manufacturing practice (GMP) compliant manufacturing facility, with enhanced control over end-to-end supply chain, improved operational efficiency and reduced material and production costs.

10+
%
EBITDA
growth

EZZ

Q&A

For personal use only
EZZ



EZZ LIFE SCIENCE HOLDINGS LIMITED

[ASX: EZZ]

EZZ

EZZ Life Science Holdings Limited
ABN 83 608 363 604

104 Derby Street,
Silverwater NSW 2128

T: 02 9160 2305
E: ir@ezzlife.com.au

www.ezzlife.com.au



[EZZLifescience](https://twitter.com/EZZLifescience)



linkedin.com/company/ez-z-life-science-holdings



[EZZAustralia](https://facebook.com/EZZAustralia)



[EZZ_Australia](https://instagram.com/EZZ_Australia)

analyst use only